Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?

In this report, we describe an AL patient who had suffered from recurrent infection during previous treatment, but who responded to and tolerated well single-agent venetoclax for more than 1 year. The present report indicates that venetoclax monotherapy may be active and safe for refractory AL amyloidosis. PMID: 32207051 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32207051?dopt=Abstract

Source: International Journal of Hematology - March 22, 2020 Category: Hematology Authors: Yip PL, Lau JSM, Lam CP Tags: Int J Hematol Source Type: research